Julie

Votre espace se prépare…

Preparing your space…

Le chargement prend plus de temps que prévu.
Réessayer
Loading is taking longer than expected.
Try again
Skip to main content

Records · procedure · next step

Medical-appliance reimbursement listing: file map

A reimbursement-listing file identifies the means, appliance or associated service, category, indications and supporting evidence. France separates LPPR listing, CNEDiMTS opinion and CEPS tariff documents. Swiss LiMA/MiGeL listing has its own federal-office and commission process, limitations and maximum remuneration rules. Marketability does not establish listing or a patient payment right. The register organises actual documents without rating clinical benefit or predicting approval.

General information and document preparation. The facts, actual procedural acts and applicable versions must be checked.

Julie’s legal research currently covers French law. The Swiss sections prepare documents; they do not establish Swiss-law product capability.

Julie by AlphaDeep

Illustrative conversation
Example question

France: what category and listing route are identified?

Julie Illustration

L.165-1 distinguishes covered products/services and generic description versus brand/commercial-name listing. A product’s commercial name does not select the route.

Read the references

Which jurisdiction and listing documents are involved? Julie’s legal research currently concerns French law.

Law:
France / Switzerland

3 free questions at signup. Avoid names and sensitive information.

France: what category and listing route are identified?

L.165-1 distinguishes covered products/services and generic description versus brand/commercial-name listing. A product’s commercial name does not select the route.

France: where does the manufacturer/distributor submit?

R.165-7 specifies the health/social-security ministers with simultaneous CNEDiMTS copy, and a separate CEPS copy with tariff information.

Prepare the records

Julie’s legal research currently covers French law. The Swiss sections prepare documents; they do not establish Swiss-law product capability.

Use masked references. Nothing is sent before your explicit continuation.

Synthetic example

Product, listing-evidence and authority-stage matrix

Product
Synthetic DM1; masked supplier F1
Category
Actual listing group/route unknown
Indication
I1; no clinical assessment
Evidence
E1/E2 references only
Filing
Actual recipients and dispatch not established
Opinion
No commission opinion/decision supplied
Tariff
Proposed P1; no agreed price or reimbursement

This record organises supplied documents and values; it certifies no entitlement, permission or safety.

France: how is evidence tied to expected service?

R.165-2 distinguishes indications, populations, product interest/risks/place and public-health interest. No clinical sufficiency rating is generated here.

France: which opinion stages remain separate?

R.165-12 covers communicated opinion, observations/hearing and final opinion. Preserve actual receipt and versions without treating a draft as approval.

Switzerland: does every provider-used product follow the list?

OPAS 20 separates its specified means/appliance categories from other provider-used items remunerated through the treatment tariff.

Switzerland: where does a new-listing request go?

Article 21 directs it to the federal health office, which examines and presents it to the federal analyses/means/appliances commission. Submission is not admission.

Switzerland: what limits may an entry contain?

Article 22 permits limits such as quantity, duration, indication or age;23 separately requires lawful marketability under relevant federal/cantonal rules.

Switzerland: is a maximum the product’s accepted price?

Article 24 distinguishes applicable maximum remuneration, sale/rental costs and specified conventions. A quoted price is not an individual reimbursement conclusion.

Frequently asked questions

France: what category and listing route are identified?

L.165-1 distinguishes covered products/services and generic description versus brand/commercial-name listing. A product’s commercial name does not select the route.

France: how is evidence tied to expected service?

R.165-2 distinguishes indications, populations, product interest/risks/place and public-health interest. No clinical sufficiency rating is generated here.

Switzerland: where does a new-listing request go?

Article 21 directs it to the federal health office, which examines and presents it to the federal analyses/means/appliances commission. Submission is not admission.

Switzerland: is a maximum the product’s accepted price?

Article 24 distinguishes applicable maximum remuneration, sale/rental costs and specified conventions. A quoted price is not an individual reimbursement conclusion.

Sources and versions

  1. ch-opas-fr

    2026-08-01

  2. fr-css-L165-1
  3. fr-css-R165-12
  4. fr-css-R165-2
  5. fr-css-R165-7